Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions—The CAESAR study
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Sabrina Giometto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Neuroprotective Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute.
Abstract (Originalsprache)
Purpose
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease. Riluzole may increase survival and delay the need for mechanical ventilation. The CAESAR project (‘Comparative evaluation of the efficacy and safety of drugs used in rare neuromuscular and neurodegenerative diseases’, FV AIFA project 2012‐2013‐2014) involves evaluating prescribing patterns, and analysing effectiveness and comparative safety of drugs, in patients with neurodegenerative diseases. The aim of this study is to evaluate adherence to riluzole in patients with ALS during the first year of use, identifying adherence clusters.
Methods
A retrospective cohort study was conducted using administrative data from Latium, Tuscany, and Umbria. We identified subjects with a new diagnosis of ALS between 2014 and 2019, with the first dispensation of riluzole within 180 days of diagnosis. We considered a two‐year look‐back period for the characterization of patients, and we followed them from the date of first dispensing of riluzole for 1 year. We calculated 12 monthly adherence measures, through a modified version of the Medication Possession Ratio, estimating drug coverage with Defined Daily Dose. Adherence trajectories were identified using a three‐step method: (1) calculation of statistical measures; (2) principal component analysis; (3) cluster analysis. Patient characteristics at baseline and during follow‐up were described and compared between adherence groups identified.
Results
We included 264 ALS patients as new users of riluzole in Latium, 344 in Tuscany, and 63 in Umbria. We observed a higher frequency of males (56.2%) and a mean age of 67.4 (standard deviation, SD, 10.4) in the overall population. We identified two clusters in all regions: one more numerous, including adherent patients (60%, 74%, 88%, respectively), and another one including patients who discontinued therapy (40%, 26%, 12%, respectively). In Tuscany patients discontinuing riluzole more frequently died (28.6% vs. 15.4%, p ‐value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Department of Epidemiology, ASL Roma 1, SSR Lazio, Rome, Italy.
- Regional Health Agency of Tuscany, Florence, Italy.
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
- Hospital of Perugia, Neurophysiopathology, Perugia, Italy.
- National Center for Disease Prevention and Health Promotion, Italian National Institute of Health, Rome, Italy.
ORCID-Profile: Marco Finocchietti, Niccolò Lombardi, Ersilia Lucenteforte
Förderung
- Agenzia Italiana del Farmaco, Ministero della Salute
Zitieren
APA
Giometto, S., Finocchietti, M., Paoletti, O., Lombardi, N., Celani, M. G., Sciancalepore, F., Lucenteforte, E., Kirchmayer, U., & CAESAR study group (2024). Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions—The CAESAR study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5736
Vancouver
Giometto S, Finocchietti M, Paoletti O, Lombardi N, Celani MG, Sciancalepore F, et al. Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions—The CAESAR study. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5736
BibTeX
@article{Giometto2024,
author = {Giometto, Sabrina and Finocchietti, Marco and Paoletti, Olga and Lombardi, Niccolò and Celani, Maria Grazia and Sciancalepore, Francesco and Lucenteforte, Ersilia and Kirchmayer, Ursula and CAESAR study group, CAESAR study group},
title = {Adherence to riluzole therapy in patients with amyotrophic lateral sclerosis in three Italian regions—The CAESAR study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5736}
}
EUVIMED